MRI Screening of Placenta Adhesion Abnormalities

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorCentral Hospital, Nancy, France

About this trial

Placenta Adhesion Abnormalities (PAA) are the consequence of an excessive invasion of the placenta within the myometrium. PAA are related to severe maternal pregnancy outcomes, especially in case of incidental discovery during delivery that increase the risk of intraoperative massive bleeding, hysterectomy and even maternal death. Ultrasound is the standard modality for diagnosing PAA, but Magnetic Resonance Imaging (MRI) has been increasingly performed in the case of inconclusive sonographic findings. However, standard morphological MRI sequences appear as insufficient to improve the sensitivity and specificity values for detecting PAA, while quantitative MRI may be more efficient.

The main objective of this study is to characterize the diagnostic performance of quantitative MRI parameters (mainly Apparent Diffusion Coefficient, T2 and T2\*) reflecting placental perfusion and/or oxygenation at high field, without injection of gadolinium-based agent, for the detection of PAA in women with ongoing pregnancy between 30 and 38 weeks of gestation with risk factors for PPA.

Eligibility criteria

Qualifiers

Pregnant participant between 30 and 38 weeks of gestation,

Age ≥18 years old,

Participant who completed the preliminary medical examination,

Participant who has received full information about the organization of the research and has signed her informed consent.

Disqualifiers

Multiple pregnancy,

Participant presenting at least one contraindication or restriction to performing an MRI as described in the protocol, in accordance with the current recommendations,

Participant unable to understand or follow study procedure,

Person referred to in Articles L. 1121-6 to L. 1121-8, L1122-2 and L. 1122-1-2 of the Public Health Code.

Trial design

Treatments tested in this trial

  • MRI

Treatment groups

71 Participants
are divided into 1 treatment group